Firms
Clarevia Ventures
Clarevia Ventures is a Midwest healthcare venture capital firm formerly known as Venture Investors Health Fund. It announced the rebrand on May 6, 2026 and invests in early-stage medical devices, diagnostics, digital health and pharmaceutical innovations, including university research spinouts. Its AI, deep technology and neuroscience portfolio includes EarliPoint Health's eye-tracking autism assessment, EnsoData's AI sleep testing, Neurovance's neuropsychiatric therapeutics and HistoSonics' ultrasound-based tissue treatment. Its public team directory lists Managing Partner Jim Adox, Partners Scott Button, Paul Weiss, David Arnstein and John Neis, Chief Medical and Scientific Officer Joe Amaral, Principal Jenni Le, Venture Partners Margaret Kaczor Andrew and Shelly Lanning, Executive in Residence Cheryl R. Blanchard, Controller Becky Hoerman and Office Manager Linda Olson. Arnstein is also CFO. The firm closed Venture Investors Health Fund 6 at $75 million in October 2019 and its seventh fund at $80 million in September 2025. It co-led EarliTec's $21.5 million Series B in April 2024. Its current materials report $350 million under management; this represents firm assets across vehicles.
- Founded
- —
- Type
- Venture capital
Funds2
Team
Operations and support
 Becky HoermanController |
 Cheryl R. BlanchardExecutive in Residence |
 David ArnsteinPartner and CFO |
 Jenni LePrincipal |
 Jim AdoxManaging Partner |
 Joe AmaralChief Medical and Scientific Officer |
 John NeisPartner |
 Linda OlsonOffice Manager |
 Margaret Kaczor AndrewVenture Partner |
 Paul WeissPartner |
 Scott ButtonPartner |
 Shelly LanningVenture Partner |
Co-investing
EnsoData$20M · 2022-06-03
Fred Robertson- EnsoData$20M · 2022-06-03
Justin Mortara- EnsoData$20M · 2022-06-03
Nexus NeuroTech Ventures
EarliPoint Health$21M · 2024-04-02
Questa Capital- EnsoData$20M · 2025-06-25